Aliiakparova A Sh
Probl Endokrinol (Mosk). 1975 Jul-Aug;21(4):13-7.
The author assessed the results of the test of the triiodothyronine (T3) suppression of the I131 absorption in 10 healthy women, 22 suffering from neurocirculatory dystrophy and 35 patients with diffuse toxic goiter. This test was found to distinctly differentiate the patients with diffuse toxic goiter and healthy persons. Reduction of absorption to the level below 15% of the indicator dose with consideration to the level of the initial absorption could be considered as criterion of the normal I131 absorption in response to the T3 administration. The mean suppression of the absorption in T3 administration in patients with neurocirculatory dystonia (10.7 +/- 1.49%) displayed a significant difference from the level of mean suppression of the absorption in patients with diffuse toxic goiter (58.1 +/- 4.76%). However, in individual patients suffering from neurocirculatory dystonia the I131 absorption by the thyroid gland in T3 administration still exceeded such in healthy persons. Therefore such patients require further observation because of a possible development in them of diffuse toxic goiter.
作者评估了10名健康女性、22名患有神经循环性营养不良的患者以及35名弥漫性毒性甲状腺肿患者的三碘甲状腺原氨酸（T3）抑制I131吸收试验的结果。发现该试验能明显区分弥漫性毒性甲状腺肿患者和健康人。考虑到初始吸收水平，吸收降低至指标剂量的15%以下可被视为T3给药后I131吸收正常的标准。神经循环性肌张力障碍患者在给予T3时吸收的平均抑制率（10.7±1.49%）与弥漫性毒性甲状腺肿患者吸收的平均抑制水平（58.1±4.76%）存在显著差异。然而，在个别患有神经循环性肌张力障碍的患者中，给予T3时甲状腺对I131的吸收仍超过健康人。因此，这类患者因可能发展为弥漫性毒性甲状腺肿而需要进一步观察。
